posted by AHIP
on April 25, 2018
WASHINGTON, D.C. – America’s Health Insurance Plans (AHIP) issued the following statement regarding the U.S. Supreme Court’s decision in Oil States v. Greene’s Energy Group, which upheld the inter partes review (IPR) process as a way to prevent drug manufacturers from inappropriately prolonging patent monopolies past the time intended by Congress.
“Patients had a lot at stake in the Supreme Court’s determination. Congress designed inter partes review as a quick and cost-effective way to weed out weak patents – including patents for branded prescription drugs. By upholding a faster and less costly patent review process, the Supreme Court has protected an important pathway that allows generic prescription drugs to get to patients faster. Generic drugs increase competition and choice in the market, which helps to lower drug prices. We applaud the Supreme Court’s decision, which will help ensure that millions of Americans get faster access to more affordable, lifesaving medicines.”